Related Experiment Videos
Fas receptor-mediated apoptosis: a clinical application?
Tineke Timmer1, Elisabeth G E de Vries, Steven de Jong
1Division of Medical Oncology, University Hospital Groningen, The Netherlands. t.timmer@int.azg.nl
The Journal of Pathology
|January 17, 2002
Summary
Targeting Fas-mediated apoptosis with anti-Fas antibodies shows promise for cancer therapy. However, resistance and liver toxicity necessitate exploring combination therapies and localized Fas ligand delivery strategies.
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Background:
- Fas (also known as CD95 or APO-1) is a death receptor crucial for initiating apoptosis.
- Fas-mediated apoptosis can be triggered by Fas ligand (FasL) or agonistic anti-Fas antibodies, leading to caspase activation.
- Many tumors express Fas, making it a potential therapeutic target for cancer treatment.
Purpose of the Study:
- To explore the potential of targeting Fas-mediated apoptosis as an anticancer therapy.
- To investigate mechanisms of resistance to Fas-mediated apoptosis.
- To evaluate combination therapy strategies involving anti-Fas antibodies or FasL with cytotoxic drugs.
Main Methods:
- In vivo studies using solid tumors implanted in mice.
- Administration of anti-Fas antibodies, FasL-expressing cells, or recombinant FasL (rFasL).
- Investigation of tumor sensitivity to Fas-mediated apoptosis.
Main Results:
- Fas-mediated apoptosis can be induced by anti-Fas antibodies, FasL-expressing cells, or rFasL in tumors.
- Resistance to Fas-mediated apoptosis occurs due to various inhibition mechanisms and potential mutations in Fas or p53.
- Systemic administration of anti-Fas antibodies or rFasL resulted in significant liver toxicity.
Conclusions:
- Targeting Fas-mediated apoptosis is a promising anticancer strategy, but clinical application is limited by resistance and toxicity.
- Combination therapy with cytotoxic drugs may enhance efficacy.
- Local administration of FasL or gene therapy using inducible FasL vectors are potential strategies to overcome systemic toxicity and improve therapeutic outcomes.